20 registrations that name vasopressin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 20 registrations
Status
Phase
23US sites across 16 states
1
2 to 4
5 to 19
20 or more
All 20 registrations
RecruitingNCT05958342
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Phase 2
Jason Sperry
About 1,050 people
Started Jun 30, 2024
In plain words A Phase 2 study of vasopressin in people 18 to 90, run by Jason Sperry. It plans to enroll about 1,050 people at 18 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Trauma; Hemorrhage.
What it tests, as registered
Calcium Gluconate; Vasopressin; saline placebo
Registered summary
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.
Where, as registered
18 US sites in 14 states.
RecruitingNCT02118467
Vasoactive Drugs in Intensive Care Unit
Phase 4
University of Chicago
About 836 people
Started May 15, 2014
In plain words A Phase 4 study of vasopressin in people 18 and older, run by University of Chicago. It plans to enroll about 836 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Shock.
Age greater than or equal to 18 years old
Requirement for vasoactive drugs via a central venous catheter for the treatment of shock. Shock will be defined as mean arterial pressure less than 70 mmHg or systolic blood pressure less than 100 mmHg despite administration of at least…
The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.
Where, as registered
1 US site in 1 state.
RecruitingNCT06709573
Early Versus Late Adjunctive Vasopressin in Septic Shock
Phase 4
The Cleveland Clinic
About 300 people
Started Apr 29, 2025
In plain words A Phase 4 study of vasopressin in people 18 and older, run by The Cleveland Clinic. It plans to enroll about 300 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sepsis; Septic Shock.
Age ≥ 18 Years
Diagnosis of Septic Shock
Admitted to Cleveland Clinic Main Campus Medical ICU
Receiving continuous infusion of norepinephrine at a dose > 5 mcg/min at time of enrollment
The exclusion criteria are on the listing.
What it tests, as registered
vasopressin - early initiation; vasopressin - standard initiation
Registered summary
The goal of the CASPER-Pilot study is to develop clinical decision support (CDS) technology within Epic to randomize patients with septic shock to early versus standard of care vasopressin initiation. The primary aim of this study will be to test the hypothesis that CDS technology can be utilized to create two distinct cohorts of patients reflecting different times of vasopressin initiation based on norepinephrine dose requirements. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT03446456
Vasopressin and Pain Perception in the Brain
Phase 1 and 2
University of Maryland, Baltimore
About 56 people
Started Sep 17, 2018
In plain words A Phase 1 and 2 study of vasopressin in people 18 to 65, run by University of Maryland, Baltimore. It plans to enroll about 56 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Acute Pain.
Age ( 18-55 years old)
English speaker (written and spoken)
The exclusion criteria are on the listing.
What it tests, as registered
Arginine vasopressin; Saline; Observational learning; fMRI data aquisition
Registered summary
The feeling of pain is not just a sensory experience, but is also influenced by emotions, beliefs and expectations, making pain a highly subjective experience. This is evident in clinical practice, where the behavior of the physician and the treatment context can strongly influence the pain experience of patients. Research has shown that patients' expectation that a treatment will reduce pain influences individual perception of pain, even if the treatment has no active ingredient. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07102615
Intracervical Vasopressin
Phase 4
Prisma Health-Upstate
About 50 people
Started Oct 30, 2025
In plain words A Phase 4 study of vasopressin in female participants 18 to 51, run by Prisma Health-Upstate. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 51. Conditions: Retained Products of Conception.
Women
Aged 18-51
Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion
The exclusion criteria are on the listing.
What it tests, as registered
Intracervical injection of Vasopressin; Intracervical Injection of saline
Registered summary
This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06464510
Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis
Phase 3
Hospital do Coracao
About 2,800 people
Started Nov 21, 2024
In plain words A Phase 3 study of vasopressin in people 18 and older, run by Hospital do Coracao. It plans to enroll about 2,800 people at 8 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Septic Shock.
Patients with vasopressor dependent sepsis, defined by infection suspicion and antibiotic administration or laboratory confirmed viral infection, plus hypotension with the need of vasopressors for at least one hour;
Admitted or expected to be admitted to the ICU in the next 12 hours
Adequate volume resuscitation in the opinion of the attending physician
Use of norepinephrine > 0.05μg/Kg/min and ≤ 0.25μg/Kg/min for at least 1 hour and at most 24 hours at the time of inclusion
The exclusion criteria are on the listing.
What it tests, as registered
Early Vasopressin; Norepinephrine and Vasopressin for Rescue
Registered summary
The norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation only as a rescue strategy for hemodynamic management of critically ill patients with vasopressor dependent sepsis.
Where, as registered
No US site; Brazil (8).
RecruitingNCT05139849
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
Phase 3
Tiohundra AB
About 1,276 people
Started Nov 17, 2021
In plain words A Phase 3 study of vasopressin in people 18 and older, run by Tiohundra AB. It plans to enroll about 1,276 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial.
Hospitalized men > 18 years and hospitalized women > 50 years.
This is an investigator initiated randomized, placebo controlled, double blind, superiority, multi-centre clinical trial. The estimated study project period runs over 3-4 years, including pilot phase. Based on preliminary assumptions, to confirm or reject an increase in survival from 9% to 14%, about1400 patients will be randomized in the study. In hospital cardiac arrest patients meeting criteria(s) for adrenaline administration according to current ERC guidelines are eligible for randomization in the study. The full summary is on the listing.
Where, as registered
No US site; Sweden (2).
RecruitingNCT07255378
Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
Observational
Jamil Cedeño Mora
About 1,200 people
Started Oct 1, 2025
In plain words An observational study of vasopressin in people 18 and older, run by Jamil Cedeño Mora. It plans to enroll about 1,200 people at 12 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Septic Shock.
ICU admission with a septic shock diagnosis.
Age 18 years or above at ICU admission.
Use of vasopressin as an adjunct of norepinephrine.
Sustained arterial hypotension or serum lactate above 2 mmol/L.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.
Registered summary
The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock. The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin. The full summary is on the listing.
Where, as registered
No US site; Spain (12).
RecruitingNCT06934798
Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery
Phase 4
University of Sao Paulo
About 350 people
Started Apr 1, 2024
In plain words A Phase 4 study of vasopressin in people 18 and older, run by University of Sao Paulo. It plans to enroll about 350 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Vasoplegic Syndrome of Cardiac Surgery.
Age over 18.
Patients undergoing coronary artery bypass grafting, valve surgery or both, with a diagnosis of vasoplegic syndrome in the immediate postoperative period (<24 hours), defined as mean arterial pressure < 65 mmHg (measured using an invasive…
This is a randomized, double-blind clinical trial designed to compare the inotropic effects of vasopressin versus norepinephrine in patients who develop vasoplegic syndrome in the immediate postoperative period following cardiac surgery. Vasoplegic syndrome is characterized by severe hypotension due to systemic vasodilation, despite adequate fluid resuscitation and preserved or elevated cardiac output. Vasopressors are essential in restoring hemodynamic stability in this context; however, their impact on myocardial performance remains uncertain. The full summary is on the listing.
Where, as registered
No US site; Brazil (1).
RecruitingNCT06344442
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
Phase 3
Assistance Publique - Hôpitaux de Paris
About 304 people
Started Apr 16, 2025
In plain words A Phase 3 study of vasopressin in people 18 and older, run by Assistance Publique - Hôpitaux de Paris. It plans to enroll about 304 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Acute Kidney Injury Post Liver Transplantation.
Age ≥ 18 years
Any adult patient with a scheduled liver transplantation
All participants will need to be given clear information about the study and give signed informed consent.
Person affiliated to the Social Security
The exclusion criteria are on the listing.
What it tests, as registered
Arginine vasopressin; Norepinephrine
Registered summary
Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality. Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. The full summary is on the listing.
Where, as registered
No US site; France (1).
RecruitingNCT04053478
Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study
No phase
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
About 144 people
Started Jul 8, 2019
In plain words A study of vasopressin in female participants 19 to 40, run by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. It plans to enroll about 144 people at 1 site, none in the US.
Hypotension is one of the most common adverse effects of spinal anesthesia for cesarean deliveries, affecting as many as 55-90% of mothers. Hypotension during cesarean deliveries can have detrimental effects on the mother and neonate. Various vasopressors, such as ephedrine, phenylephrine and more recently norepinephrine, have been used for the prevention and treatment of hypotension at cesarean deliveries. Ephedrine was historically considered as the gold standard vasopressor for the management of hypotension during cesarean deliveries. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07838493
Oromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention
No phase
University of Electronic Science and Technology of China
About 120 people
Starts Sep 18, 2026 (estimated)
In plain words A study of vasopressin in people 18 to 30, run by University of Electronic Science and Technology of China. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 30; healthy volunteers accepted. Conditions: Healhty.
Healthy subjects without past or current psychiatric or neurological disorders
Normal or corrected-to-normal vision
Eligible for MRI scanning and willing to undergo blood sampling and study treatment administration
For naturally cycling female participants, willingness and ability to complete the experimental session within the predefined menstrual-cycle phase, determined using menstrual history and urinary luteinizing hormone (LH) testing
1 more inclusion criterion and the exclusion criteria are on the listing.
The goal of this clinical trial is to learn how 24 IU oxytocin (OT) and 24 IU arginine vasopressin (AVP), administered through the oral mucosa, affect attention to emotional faces and related brain activity in healthy adults. The study will compare OT and AVP with a placebo (PLC). The main questions it aims to answer are: 1. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07067866
Weaning Approaches for Vasopressin in Sepsis
Phase 3
Hospital Nossa Senhora da Conceicao
About 82 people
Started Oct 1, 2025
In plain words A Phase 3 study of vasopressin in people 18 and older, run by Hospital Nossa Senhora da Conceicao. It plans to enroll about 82 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Septic Shock.
Age over 18 years
Admitted to the Intensive Care Unit
Patients with vasopressor dependent sepsis
Receiving combined norepinephrine and vasopressin therapy
The exclusion criteria are on the listing.
What it tests, as registered
Titrated weaning of vasopressin.; Abrupt weaning of vasopressin.
Registered summary
In this study, we aim to evaluate the incidence of hypotension during vasopressin weaning by comparing two methods - titrated reduction versus abrupt withdrawal - through the conduct of a randomized clinical trial.
Where, as registered
No US site; Brazil (1).
RecruitingNCT06547892
Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU
Phase 2
Hospital do Coracao
About 60 people
Started Apr 10, 2025
In plain words A Phase 2 study of vasopressin in people 18 and older, run by Hospital do Coracao. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Critical Illness.
Adult patients (≥18 years old);
Admitted to intensive care units;
Predicted risk of acute kidney injury calculated based on clinical and laboratory data at ICU admission and is considered eligible if the value in the calculator is equal or greater than 5 points;
The exclusion criteria are on the listing.
What it tests, as registered
Vasopressin; 0,9% saline solution
Registered summary
Renal dysfunction is a frequent complication in patients admitted to intensive care units (ICUs), associated with high morbidity and mortality. Current therapeutic options to prevent this condition are limited and lack robust scientific evidence. This pilot study consists of a multicenter, blinded, randomized clinical trial, unprecedented in the literature to date, aiming to fill this knowledge gap and offer new therapeutic perspectives to improve renal outcomes in critically ill patients admitted to the ICU.
Where, as registered
No US site; Brazil (1).
RecruitingNCT06234592
The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
No phase
King's College Hospital NHS Trust
About 45 people
Started Jan 5, 2024
In plain words A study of vasopressin in people 18 and older, run by King's College Hospital NHS Trust. It plans to enroll about 45 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Septic Shock; Acute Kidney Injury.
Within 48 hours of intensive care admission
Evidence of suspected or confirmed infection
Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)
Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of >0.1mcg/kg/min
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Angiotensin II; Vasopressin; Norepinephrine
Registered summary
Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.
Where, as registered
No US site; United Kingdom (1).
Not yet recruitingNCT07633600
Phenotype Guided Vasoactive Medication During Kidney Transplantation
Phase 4
Jennifer Cutler
About 255 people
Starts Jun 1, 2026 (estimated)
In plain words A Phase 4 study of vasopressin in people 18 and older, run by Jennifer Cutler. It plans to enroll about 255 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Kidney Transplant; Fluid Management.
Adults aged 18 years or older
Undergoing kidney transplantation at Cedars-Sinai Medical Center
Able to provide informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Phenotype-Guided Vasoactive Management
Registered summary
The goal of this clinical trial is to learn if vasopressin improves the body's response to intravenous fluids during kidney transplantation in patients who have relaxed blood vessels. Researchers will compare the results of vasopressin to those who received calcium chloride.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07052084
Systematic Adjunction of Vasopressine in Septic Shock
Phase 3
Assistance Publique Hopitaux De Marseille
About 120 people
Starts Jan 2026 (estimated)
In plain words A Phase 3 study of vasopressin in people 18 and older, run by Assistance Publique Hopitaux De Marseille. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Septic Shock.
Patient aged 18 or over
Patient who has consented to take part in the research or patient whose close relative has consented to take part in the research or, failing that, patient being included in an emergency situation
Patient in septic shock with adapted cardiac output
Patient in whom noradrenaline dosage has been greater than 0.3μg/kg/min for less than 12 hours
1 more inclusion criterion and the exclusion criteria are on the listing.
Septic shock is a syndrome associated with severe infection and a mortality rate of approximately 45%. In line with current recommendations, norepinephrine is the first-line vasopressor used in patients with septic shock. In a previous study, norepinephrine doses above 1 µg/kg/min were associated with mortality rates over 90%. In the same study, doses above 0.3 µg/kg/min were associated with a mortality rate of 40%. An increased mortality compared to the general 40% mortality of septic shock appears to be associated with norepinephrine doses as low as 0.3 µg/kg/min. The full summary is on the listing.
Where, as registered
No US site; France (1).
Not yet recruitingNCT07614438
Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,
Phase 2
Fondation Hôpital Saint-Joseph
About 90 people
Starts Aug 1, 2026 (estimated)
In plain words A Phase 2 study of vasopressin in people 18 and older, run by Fondation Hôpital Saint-Joseph. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Anesthesia; Pulmonary Hypertension; Chronic Pulmonary Thromboembolism; Vasopressor.
Age ≥18 years;
Patient scheduled for pulmonary endarterectomy surgery;
In women of childbearing potential: negative serum pregnancy test and use of adequate contraception;
Affiliation to the French social care service;
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Vasopressin; Norepinephrine
Registered summary
Chronic thromboembolic pulmonary hypertension (CTEPH), one of the leading causes of pulmonary hypertension (PH), is caused by the chronic obstruction of the pulmonary arteries following episode of pulmonary embolism. It is the only cause of PH which is accessible to a potential curative surgical treatment: the pulmonary endarterectomy (PEA). Because of their underlying disease (pulmonary hypertension and potential right heart dysfunction), anesthesia should be performed cautiously. The full summary is on the listing.
Where, as registered
No US site; France (1).
Not yet recruitingNCT07423156
Tranexamic Acid vs Vasopressin in Placenta Previa Trial
Phase 3
Allama Iqbal Medical College
About 58 people
Starts Mar 1, 2026 (estimated)
In plain words A Phase 3 study of vasopressin in female participants 18 to 45, run by Allama Iqbal Medical College. It plans to enroll about 58 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Placenta Previa.
What it tests, as registered
Group A: Tranexamic acid; Group B: Vasopressin
Registered summary
Placenta previa is a major obstetric condition associated with increased risk of excessive blood loss during cesarean section, leading to maternal morbidity and mortality. Different pharmacological agents have been used to minimize intraoperative hemorrhage. Tranexamic acid is an antifibrinolytic agent, while vasopressin reduces blood loss by causing vasoconstriction and myometrial contraction at the injection site. Both drugs have been used separately in placenta previa cases, however direct comparison between tranexamic acid and vasopressin is limited. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
Not yet recruitingNCT06853574
Ventriculo-arterial Coupling and Myocardial Work in Sepsis and Septic Shock
No phase
General and Teaching Hospital Celje
About 30 people
Starts Feb 2025 (estimated)
In plain words A study of vasopressin in people 18 and older, run by General and Teaching Hospital Celje. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Sepsis; Septic Shock.
18 or more years old
sepsis
septic shock
The exclusion criteria are on the listing.
What it tests, as registered
Fluid therapy; Noradrenaline infusion
Registered summary
Sepsis is a term which describes an excessive response of the body to an infection and, if not promptly treated, can turn into septic shock a condition in which the organs don't receive enough oxygen to satisfy their needs. The aim of the study is to assess how the treatment of sepsis and septic shock will modify myocardial work and ventriculo-arterial coupling, that can be considered as indicators of ventricular and arterial performance efficacy respectively. The full summary is on the listing.